In Montoyas new lecture he posits the use of the drug tofacitinib (Xeljanz). This is in relation to the general cytokine behavour found in severe patients. I have already found a supplier and its aviailable from India and Turkey at around £450 per month. I feel like this would be a short term treatment if I were to try it as I have been at all levels of ME, very mild to bebdound. So I feel if it pushed me up a level I would stop the treatment and try and sustain it. Does this drug fit in with anyones current thinking of the mechanism of our disease?